Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology, developing antibody-based therapies for cancer treatment. The company became publicly traded in 2022 through a SPAC merger with Brookline Capital Acquisition Corp., sponsored by Brookline Capital Markets, which had completed its IPO in 2021. Apexigen filed an 8-K current report with the SEC on May 24, 2023, under accession number 0001193125-23-152387, disclosing a material corporate event. The company operates in the biopharmaceutical and oncology sector and has been navigating post-merger public markets as it advances its clinical pipeline. Sign up for full data, filings, and deal analytics on SpacDesk at spacdesk.com.